LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has completed the sale of its PICC and Midline product portfolios to Spectrum Vascular, an innovative medical device company focused on vascular access and medication management, for up to $45 million in cash..

纽约州莱瑟姆（商业新闻短讯）--AngioDynamics，Inc.（纳斯达克股票代码：ANGO）是一家领先且具有变革性的医疗技术公司，专注于恢复人体血管系统的健康血流，扩大癌症治疗选择并改善患者生活质量，今天宣布已完成其PICC和中线产品组合的销售，以Spectrum vascular，一家创新的医疗器械公司专注于血管通路和药物管理，现金高达4500万美元。。

The transaction consists of AngioDynamics’ PICC, Midline and tip location products. This combined portfolio of products contributed approximately $43.5 million in annual sales during AngioDynamics’ fiscal year 2023.

该交易包括AngioDynamics的PICC，中线和尖端定位产品。在AngioDynamics 2023财年，这一产品组合的年销售额约为4350万美元。

The Company also announced that it has discontinued the sale of its Uniblate and Starburst Radio Frequency products, as well as its Syntrax support catheter products to further streamline its product portfolio. These products contributed approximately $5.5 million in annual sales during AngioDynamics’ fiscal year 2023..

该公司还宣布停止销售其Uniblate和Starburst射频产品，以及Syntrax支持导管产品，以进一步简化其产品组合。在AngioDynamics 2023财年，这些产品的年销售额约为550万美元。。

“Today’s divestiture is another significant milestone in our transformation and supports our focus on driving increased penetration of our Med Tech platforms in high-growth markets. It builds upon the divestiture of our Dialysis and Biosentry businesses that we announced in June as well as the plan we announced in January to streamline our manufacturing operations,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics.

吉姆·克莱默（JimClemmer）说：“今天的剥离是我们转型的另一个重要里程碑，支持我们专注于推动我们的医疗技术平台在高增长市场中的渗透。它建立在我们6月份宣布的透析和生物浓缩业务剥离以及1月份宣布的简化制造业务计划的基础上。”，AngioDynamics总裁兼首席执行官。

“This transaction, combined with the discontinuation of our radiofrequency ablation and Syntrax products, further strengthens our balance sheet, optimizes our product portfolio and deepens our strategic focus on driving growth and profitability within our NanoKnife, Mechanical Thrombectomy and Auryon businesses.”.

“这项交易，加上我们停止使用射频消融和Syntrax产品，进一步加强了我们的资产负债表，优化了我们的产品组合，加深了我们对推动纳米刀、机械血栓切除术和Auryon业务增长和盈利能力的战略重点。”。

Mr. Clemmer added, “The acquisition of our PICC and Midline portfolios provides Spectrum Vascular with strong, well-recognized product lines and a skilled commercial team. We are pleased that Spectrum Vascular, a growing provider of vascular access products, is acquiring our PICC and Midline portfolios and will continue to expand patient access to these industry-leading, high-quality medical devices.”.

克莱默补充道，“收购我们的PICC和中线产品组合为Spectrum Vascular提供了强大、公认的产品线和一支熟练的商业团队。我们很高兴Spectrum Vascular，一家不断增长的血管通路产品供应商，正在收购我们的PICC和中线产品组合，并将继续扩大患者对这些行业领先的高质量医疗设备的访问。”。

The transaction consideration consists of $34.5 million paid at closing, an earnout related to sales of the divested products over the next two years equal to $5.5 million, and a milestone payment of $5 million paid upon final transfer of the manufacturing of the divested products to a third-party manufacturer..

交易对价包括交割时支付的3450万美元，与未来两年出售剥离产品相关的收入相当于550万美元，以及在将剥离产品的制造最终转让给第三方制造商时支付的500万美元里程碑付款。。

The assets divested and discontinued today, along with the assets divested in June, will be accounted for as discontinued operations, removing their impact from the Company’s fiscal 2024 results. The divestiture of the PICC and Midline businesses, together with the discontinuance of the radiofrequency ablation and Syntrax businesses, will reduce full-year fiscal 2024 revenue by approximately $50 million.

今天剥离和停产的资产以及6月份剥离的资产将被视为停产经营，从而消除其对公司2024财年业绩的影响。剥离PICC和中线业务，以及停止射频消融和Syntrax业务，将使2024财年全年收入减少约5000万美元。

The Company expects that the divestiture of the PICC and Midline businesses, together with the discontinued businesses, will be accretive to full-year fiscal 2024 gross margin..

该公司预计，人保和中线业务以及已停业业务的剥离将增加2024财年全年的毛利率。。

In connection with the transactions announced today, the Company will eliminate certain sales, marketing and operational expenses. Today’s transaction, inclusive of the restructuring, is expected to be slightly dilutive to fiscal 2024 adjusted earnings per share.

就今天宣布的交易而言，该公司将取消某些销售、营销和运营费用。今天的交易（包括重组）预计将略微稀释2024财年调整后的每股收益。

The Company will provide updated fiscal 2024 financial guidance on its fiscal third quarter earnings call in early April.

该公司将于4月初就其第三季度财报电话会议提供最新的2024财年财务指导。

UBS Investment Bank is serving as financial advisor, and Cadwalader, Wickersham & Taft is serving as legal advisor to AngioDynamics. Fried Frank is serving as legal advisor to Specturm Vascular.

瑞银投资银行（UBS Investment Bank）担任财务顾问，Cadwalader，Wickersham&Taft担任AngioDynamics的法律顾问。Fried Frank担任Specturm Vascular的法律顾问。

About AngioDynamics, Inc.

关于AngioDynamics，Inc。

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life.

AngioDynamics是一家领先且具有变革性的医疗技术公司，专注于恢复人体血管系统的健康血流，扩大癌症治疗选择并改善患者的生活质量。

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

该公司的创新技术和设备是由快速增长的医疗保健市场中的天才医生选择的，用于治疗未满足的患者需求。有关更多信息，请访问www.angiodynamics.com。

About Spectrum Vascular

关于Spectrum Vascular

Spectrum Vascular is an innovative medical device company focused on vascular access and medication management. The company's mission is to improve the lives of patients worldwide by providing caregivers with high quality, innovative products with exceptional customer service. Innovation has been a core strategic pillar throughout Spectrum Vascular's history and many of its products have been designed to deliver antimicrobial protection and thrombus reduction.

Spectrum Vascular是一家专注于血管通路和药物管理的创新医疗器械公司。该公司的使命是通过为护理人员提供高质量的创新产品和卓越的客户服务，改善全球患者的生活。创新一直是Spectrum Vascular历史上的核心战略支柱，其许多产品旨在提供抗菌保护和血栓减少。

Spectrum Vascular is a portfolio company of Event Capital Strategies, a medical technology-focused investment fund based in New York..

Spectrum Vascular是Event Capital Strategies的投资组合公司，总部位于纽约，是一家专注于医疗技术的投资基金。。

Safe Harbor

安全港

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。关于AngioDynamics公司预期未来财务状况、经营成果、现金流、业务战略、预算、预计成本、资本支出、产品、竞争地位、增长机会、未来经营管理计划和目标的所有报表，以及包括“预期”、“重申”、“打算”等字样的报表“预期”、“计划”、“相信”、“寻求”、“估计”、“项目”、“乐观”或此类词语和类似表达的变体都是前瞻性陈述。

These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign healthcare reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigat.

这些前瞻性陈述并不能保证未来的表现，并且会受到风险和不确定性的影响。投资者应注意，实际事件或结果可能与血管动力学的预期（明示或暗示）存在实质性差异。可能影响AngioDynamics取得实际成果的因素包括但不限于新型冠状病毒全球大流行的规模和范围、AngioDynamics开发现有和新产品的能力、竞争对手取得的技术进步和专利、侵犯AngioDynamics技术或声称AngioDynamics技术侵犯第三方技术、AngioDynamics有效竞争拥有更大资源的竞争对手的能力、FDA或其他监管机构的未来行动、国内外医疗改革和政府法规、未决或未来临床试验的结果、整体经济状况（包括通货膨胀、劳动力短缺和供应链挑战，包括原材料的成本和可用性）、正在进行的诉讼的结果。

AngioDynamics, the AngioDynamics logo and Auryon are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are property of their respective owners.

AngioDynamics、AngioDynamics徽标和Auryon是AngioDynamics，Inc.，一家附属公司或子公司的商标和/或注册商标。所有其他商标均为其各自所有者的财产。